Erick Gamelin

Insider Reports History

Location
Watertown, MA
Signature
/s/ Adam D. Levy, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Erick Gamelin:

Company Role Class Num Shares Value Price $ Report Date Ownership
Acrivon Therapeutics, Inc. Chief Development Officer Common Stock 15,283 $34,233 $2.24 14 Nov 2025 Direct
Acrivon Therapeutics, Inc. Chief Development Officer Stock Option (Right to Buy) 78,078 01 Mar 2025 Direct

Insider Reports Filed by Erick Gamelin

Symbol Company Period Transactions Value $ Form Type Role Filing Time
ACRV Acrivon Therapeutics, Inc. 14 Nov 2025 1 -$902 4 Chief Development Officer 18 Nov 2025, 16:30
ACRV Acrivon Therapeutics, Inc. 14 Aug 2025 1 -$560 4 Chief Development Officer 18 Aug 2025, 17:16
ACRV Acrivon Therapeutics, Inc. 14 May 2025 1 -$459 4 Chief Development Officer 16 May 2025, 16:18
ACRV Acrivon Therapeutics, Inc. 01 Mar 2025 1 $0 4 Chief Development Officer 04 Mar 2025, 17:24
ACRV Acrivon Therapeutics, Inc. 14 Feb 2025 1 -$2,541 4 Chief Development Officer 19 Feb 2025, 16:54
ACRV Acrivon Therapeutics, Inc. 14 Nov 2024 1 -$3,183 4 Chief Development Officer 18 Nov 2024, 16:29
ACRV Acrivon Therapeutics, Inc. 14 Aug 2024 1 -$2,822 4 Chief Development Officer 16 Aug 2024, 16:50
ACRV Acrivon Therapeutics, Inc. 14 May 2024 1 -$3,360 4 Chief Development Officer 16 May 2024, 18:58
ACRV Acrivon Therapeutics, Inc. 01 Mar 2024 1 $0 4 Chief Development Officer 27 Nov 2024, 18:08
ACRV Acrivon Therapeutics, Inc. 14 Feb 2024 1 -$1,591 4 Chief Development Officer 16 Feb 2024, 17:10
ACRV Acrivon Therapeutics, Inc. 14 Nov 2023 1 -$7,086 4 Chief Medical Officer 16 Nov 2023, 19:41
ACRV Acrivon Therapeutics, Inc. 14 Nov 2022 2 $0 4 Chief Medical Officer 16 Nov 2022, 18:21
ACRV Acrivon Therapeutics, Inc. 09 Nov 2022 0 $0 3 Chief Medical Officer 09 Nov 2022, 19:30